Trachoma Alternative Indicators Study

Data review

31 August – 1 September 2016

World Health Organization, Geneva, Switzerland

Strategic and Technical Advisory Group for Neglected Tropical Diseases

Working Group on Monitoring and Evaluation

World Health Organization
This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization.
Acknowledgements

This meeting report was drafted by Sophie Phelan, Diana L. Martin and Anthony W. Solomon, and reviewed for content by meeting participants and by Julius Schachter (University of California, San Francisco).

Data reviewed during the meeting were generated as part of studies that received generous financial support from the following agencies: (i) the Coalition for Operational Research on Neglected Tropical Diseases, which is coordinated by The Task Force for Global Health and funded through grants by the Bill & Melinda Gates Foundation and the United States Agency for International Development through its Neglected Tropical Diseases – Support Center Program; (ii) the National Eye Institute through grant EY022584 to Sheila K. West; (iii) the United Kingdom’s Department for International Development through the Global Trachoma Mapping Project grant (ARIES: 203145) to Sightsavers; (iv) the United States Agency for International Development through the ENVISION project implemented by RTI International under cooperative agreement number AID-OAA-A-11-00048, and the END in Asia project implemented by FHI360 under cooperative agreement number OAA-A-10-00051; and (v) the Wellcome Trust through an Intermediate Clinical Fellowship (098521) to Anthony W. Solomon.
## Contents

Abbreviations...........................................................................................................................................v

1. Background........................................................................................................................................1
2. Trachoma grading, tests for infection, and tests for antibodies..............................................1
3. Data from the Trachoma Alternative Indicators Study...............................................................3
4. Conclusions.......................................................................................................................................5
5. Recommendations..........................................................................................................................6

References............................................................................................................................................9

Annex 1. Meeting agenda......................................................................................................................10
Annex 2. List of participants................................................................................................................11
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC</td>
<td>United States Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>Pgp</td>
<td>plasmid gene product 3</td>
</tr>
<tr>
<td>TF</td>
<td>trachomatous inflammation—follicular</td>
</tr>
<tr>
<td>ROC</td>
<td>receiver operating characteristic</td>
</tr>
</tbody>
</table>
1. **Background**

1.1 Trachoma causes blindness through repeated conjunctival infection with *Chlamydia trachomatis* (1). To eliminate trachoma as a public health problem (2), the World Health Organization (WHO) recommends use of the SAFE strategy (that is, surgery for advanced disease; mass drug administration of antibiotics to clear *C. trachomatis* infection; and facial cleanliness and environmental improvement to reduce transmission) (3). Current (2006) guidelines (4) on the implementation of the A, F and E components are based on the prevalence of the sign “trachomatous inflammation—follicular”, or TF (5), in children aged 1–9 years.

1.2 As the prevalence of TF in 1–9-year-olds declines towards the elimination threshold of 5%, so too does the positive predictive value of TF for conjunctival *C. trachomatis* infection at both the individual and community levels (6–9). Consequently, implementation of interventions against trachoma (particularly mass drug administration of antibiotics) (1) could, in some contexts, continue for longer than necessary to meet trachoma-related public-health goals.

1.3 A further consequence of declines in the prevalence of TF in 1–9-year-olds is that it becomes progressively more difficult to train graders to recognize TF (10, 11), and to prove that they can do so accurately through formal inter-grader agreement exercises (12).

1.4 The Trachoma Alternative Indicators Study was initiated in 2014 to examine, in a variety of settings, the relationships between the district-level prevalence of TF and (i) the district-level prevalence of conjunctival *C. trachomatis* infection, and (ii) the district-level prevalence of antibodies to *C. trachomatis*-derived antigens, in order to determine whether one or both should be used as adjuncts or alternatives for deciding whether to stop mass drug administration of antibiotics in trachoma elimination programmes. The study responds, in part, to recommendations made at a 2014 Technical Consultation on Trachoma Surveillance (13).

1.5 The purpose of this meeting was to undertake an objective, open review of data generated by the study to date, consider implications for global policy and plan further work. The meeting agenda is presented as Annex 1. Participants are listed in Annex 2.

2. **Trachoma grading, tests for infection, and tests for antibodies**

2.1 In discussions of the advantages and disadvantages of the potential programmatic use of tests for *C. trachomatis* infection or for anti-*C. trachomatis* antibodies (7, 8), it is often implicitly assumed that (i) the current method for characterizing a population's requirements for interventions – namely, examination by trained graders of the conjunctivae of 1–9-year-olds for the presence or absence TF – costs nothing other than the cost of fieldwork to undertake the actual surveys, while (ii) deploying an assay would add the cost of assays to the same fieldwork costs. This comparison is flawed. Training and certifying trachoma graders costs money.

2.2 Between December 2012 and January 2016, the Global Trachoma Mapping Project undertook standardized training of 611 field teams to complete trachoma prevalence surveys

---

1 Health promotion (to achieve – among other objectives – facial cleanliness) and provision of safe water and sanitation (to achieve environmental improvement) may be advantageous regardless of whether trachoma is a public health problem or not.
in 29 countries (14). Each team was composed of one grader and one data recorder. Training consisted of an intensive five-day standardized programme (15). The readiness of trainee graders to participate in fieldwork was assessed through live-subject inter-grader agreement exercises involving 50 eyes of 50 children, with the assessments of an internationally-certified grader trainer used as the gold standard; a kappa score of ≥ 0.70 was required to pass (12). Trainee recorders’ readiness to participate in fieldwork was assessed through a similarly standardized test (12). Data on costs were collected from training of 553 teams for 17 countries. Costs included in the analysis were participants’ per diems, accommodation, training venue hire, vehicle hire and fuel for fieldwork, and training supplies; costs of international flights, per diems for international trainers and epidemiologist salaries were included in global support costs rather than training costs, because they were not exclusively attributable to training. The mean cost of training was US$ 1953 per team (16), approximately one quarter of which could be attributed to training graders to reliably diagnose TF, and to prove that they were able to do so. Each team mapped a mean of 1.2 evaluation units of which each required examination of approximately 1019 1–9-year-olds (12). This translates to a training cost (excluding costs of international support) amounting to US$ 0.39 per 1–9–year-old examined. This cost is likely to rise considerably as TF elimination thresholds are reached, because of the need to transport trainee graders to settings in which TF is still sufficiently abundant to facilitate training and testing (10, 11).

2.3 A variety of types of assay are available for the detection of conjunctival C. trachomatis infection: microscopy using Giemsa or fluorescent antibodies, culture, enzyme immunoassay, nucleic acid hybridization and nucleic acid amplification-based tests. The latter, which include commercial and in-house tests that employ the polymerase chain reaction (PCR), have the highest sensitivity and specificity and are therefore the best tests to detect C. trachomatis. Their cost (usually US$ 8–16 per test) can be somewhat contained by pooling samples (17, 18), although this increases specimen handling time and may reduce sensitivity for detection of low-load infections. Children do not necessarily relish having swabs rubbed on their everted conjunctivae.

2.4 A variety of types of assay are available for the detection of antibodies to C. trachomatis antigens in serum. Blood can be collected via venepuncture or finger-prick and stored as whole blood, serum or dried blood spots on filter paper. Tests can be conducted using enzyme-linked immunosorbent assay (ELISA) (19), lateral flow-based rapid tests (20, 21) or bead-based immunoassays (22–27); the latter facilitates multiplex testing, potentially allowing integrated surveillance for multiple different diseases simultaneously (28, 29). Studies to date have measured antibodies directed against the C. trachomatis antigens Pgp3 and CT694 (24). Seroprevalence curves of anti-C. trachomatis antibodies against age in children are believed to reflect the intensity of C. trachomatis transmission over time. Unfortunately, no currently available test measures antibodies specific for exposure to trachoma-associated (as opposed to urogenital infection-associated) C. trachomatis strains. A longitudinal study of individuals in a high prevalence community in Kongwa District, United Republic of Tanzania, did not detect seroreversion in 1–6-year-olds during the 6 months after mass antibiotic treatment (25). In low prevalence settings, at 12 months after treatment, 2–6% of previously seropositive 1–9-year-olds are seronegative. There may be an association between the amount of antibody present in serum at baseline and the likelihood of seroreversion.

2.5 There are currently no international reference standards for undertaking or interpreting C. trachomatis serological assays (19).
3. **Data from the Trachoma Alternative Indicators Study**

3.1 The data available to date are summarized in the Table below.

3.2 Infection and antibody data were collected as research adjuncts of planned trachoma elimination programme activities: baseline surveys in the Lao People’s Democratic Republic; impact surveys in Malawi and Uganda; and pre-validation surveillance surveys in Gambia, Ghana, Nepal and the United Republic of Tanzania.

3.3 The prevalence of TF in 1–9-year-olds was below the 5% elimination threshold in all surveyed evaluation units, except for three in Malawi.

3.4 Where data were available, the prevalence of conjunctival *C. trachomatis* positivity, as determined using a variety of methodologies, was generally low. In only one site (Kilosa District, United Republic of Tanzania) did infection prevalence exceed 1%, and here it was only slightly above 1%, at 1.1%. In Uganda, testing in pools showed 0% infection; these were re-run as individual samples and infection prevalence remained very low at 0.3%.

3.5 ELISA testing for antibodies to Pgp3 was conducted in laboratories in Ghana, Malawi and the United Kingdom. Data from the Gambia, the Lao People’s Democratic Republic and Uganda were used to evaluate different methodologies, in order to determine thresholds for seropositivity. The ELISA testing done in Ghana will be compared to the multiplex bead array testing done at the United States Centers for Disease Control and Prevention (CDC); the testing done at CDC will also evaluate antibody responses against other neglected tropical diseases and waterborne diseases.

3.6 Significant delays in some study sites have resulted from a faulty batch of laboratory consumables, inadequate access to appropriately equipped laboratories, limited laboratory throughput and other restrictions.
Table. Data available from the Trachoma Alternative Indicators Study, August 2016

<table>
<thead>
<tr>
<th>Study site</th>
<th>Study population</th>
<th>Prevalence</th>
<th>Anti-C. trachomatis antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agago and Pader districts, Uganda (impact survey)</td>
<td>2884 children aged 1–9 years in post-intervention districts</td>
<td>2.6%</td>
<td>17.1% (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model)</td>
</tr>
<tr>
<td>Lao People’s Democratic Republic (baseline survey)</td>
<td>951 children aged 1–9 years in 3 groups of 3 “potential hot-spot” villages (10)</td>
<td>1.5%</td>
<td>15.6% (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model)</td>
</tr>
<tr>
<td>Chikwawa (C) and Mchinji (M) districts, Malawi (impact survey)</td>
<td>6076 children aged 1–9 years in 6 evaluation units after three annual rounds of high-coverage azithromycin MDA</td>
<td>4.7% in Chapananga (C) 4.6% in Ngabu Ngokwe (C) 4.4% in Kasisi (C) 7.4% in Mkanda Gumba (M) 6.0% in Luzi Kochilira (M) 5.2% in Nkwazi (M)</td>
<td>13.6% in Chikwawa, 21.7% in Mchinji (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model)</td>
</tr>
<tr>
<td>Nine districts of Ghana (pre-validation surveillance surveys)</td>
<td>12 098 children aged 1–9 years in 18 evaluation units</td>
<td>&lt; 5% for each of 18 evaluation units</td>
<td>10.6% of 7056 dried blood spots analysed to date (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model); 3.5% of 4746 samples sent to CDC (anti-Pgp3, cut-off methodology: ROC J-index)</td>
</tr>
<tr>
<td>Kilosa District, United Republic of Tanzania (pre-validation surveillance survey)</td>
<td>1474 children aged 1–9 years in a simple random sample of 30/522 hamlets (22)</td>
<td>0.4%</td>
<td>7.5% (anti-Pgp3, determined by bead-based immunoassay, cut-off methodology: ROC J-index)</td>
</tr>
<tr>
<td>Dang and Dailekh districts, Nepal (pre-validation surveillance surveys)</td>
<td>2021 children aged 1–9 years in 15–20 villages of each district (30)</td>
<td>0.1% in Dang, 0.2% in Dailekh</td>
<td>2% in 1–4-year-olds (anti-Pgp3, determined by bead-based immunoassay, cut-off methodology: ROC J-index)</td>
</tr>
<tr>
<td>Lower River Region, Gambia (pre-validation surveillance survey)</td>
<td>383 children aged 1–9 years in 20 randomly-selected enumeration areas</td>
<td>1.8% in 2013 (31)</td>
<td>6.5% (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model) in 2014</td>
</tr>
<tr>
<td>Upper River Region, Gambia (pre-validation surveillance surveys)</td>
<td>359 children aged 1–9 years in 20 randomly-selected enumeration areas</td>
<td>0.4% in 2013 (31)</td>
<td>6.1% (anti-Pgp3, determined by ELISA, cut-off methodology: mixture model) in 2014</td>
</tr>
<tr>
<td>Kongwa District, United Republic of Tanzania (impact survey with follow-up)</td>
<td>2111 children aged 1–9 years in 50 randomly-selected communities followed for one year</td>
<td>5.2%</td>
<td>30.9% (anti-Pgp3, determined by bead-based immunoassay, cut-off methodology: ROC J-index); seroconversion rate: 9.8%, seroconversion rate: 6.4%</td>
</tr>
</tbody>
</table>

ELISA, enzyme-linked immunosorbent assay; MDA, mass drug administration; PCR, polymerase chain reaction; ROC, receiver operating characteristic.
4. Discussion and conclusions

4.1 There is not yet sufficient information from this series of investigations to draw
definitive conclusions about the routine use of tests to identify either \textit{C. trachomatis} infection
or anti-\textit{C. trachomatis} antibodies, for the purpose of decision-making in trachoma elimination
programmes. Part of this uncertainty stems from the uncertainty over the true biological
significance of the 5\% TF threshold for either stopping mass administration of antibiotics or
defining re-emergence of trachoma. (Even assuming that a TF prevalence of 5\% marked a
true epidemiological watershed between populations at risk of future incident trachomatous
blindness and populations without that risk, our ability to estimate prevalence is subject to
uncertainty that can be measured, and is not negligible.)

4.2 Potential alternative or adjunct clinical indicators of conjunctival \textit{C. trachomatis}
transmission intensity (such as the prevalence of trachomatous inflammation—intense (5))
were not considered as part of the data presented at this meeting. Several participants
considered that such indices may yet have a role, although it was noted that they are likely
to have similar drawbacks as estimates of the prevalence of TF, notably (i) difficulties in
finding sufficient numbers of cases to train graders, (ii) difficulties in finding a sufficient
number of cases to prove (in inter-grader agreement exercises) that graders have been
trained well, and (iii) declining positive predictive value for conjunctival \textit{C. trachomatis}
infection as the elimination end-point is approached.

4.3 Similarly, the use of conjunctival photography was not considered in detail at this
meeting. No formal evaluation of the use of photographs for remote diagnosis of active
trachoma (33, 34) has been undertaken since high resolution digital photography became
widely available.

4.4 Laboratory capacity in many trachoma-endemic areas is inadequate. This causes
delays in sample processing in studies such as this, and would currently be problematic for
programmes if a recommendation was made to adopt the use of PCR or serology for routine
programme use. In this context, assays (such as those using lateral flow technology) that
can be performed reliably after minimal training hold particular promise. The role of an
international system for quality assurance should also be considered, taking into account the
legal requirements of and cultural issues in trachoma-endemic countries.

4.5 Studies to date have dichotomized antibody responses as positive or negative; more
information may yet be obtained by considering antibody titres quantitatively.

4.6 The lack of an international reference standard for evaluating seropositivity is limiting,
for several reasons. First, it makes it more difficult to establish cut-offs for positivity – in other
words, to distinguish signal from noise. This is a critical issue, illustrated by a recent
comparison of different methodologies for determining the cut-off (19). In Uganda, for
example, use of a receiver operating characteristic (ROC) J-index resulted in an estimated
prevalence of seropositivity of 6.8\%, whereas using a fixed mixture model the estimated
prevalence was 17.1\%. A reference standard would provide an independent mark to resolve
this inconsistency, allowing for clearer comparison between study sites and faster progress
towards determining biologically important thresholds. Second, a reference standard would
allow direct comparison of quantitative data obtained on ELISAs and bead-based assays.
Quantitative data from these assays differ based on the assay readout: ELISA optical
density data reflect the amount of light absorbed by the solution, while bead-based assays
utilize fluorescent detection. A reference standard that could be used as an internal control
would allow conversion of optical density and fluorescent readouts to a common unit,
facilitating comparison between platforms and laboratories. Data from the Trachoma
Alternative Indicators Study will compare ELISA seropositivity data generated in Ghana to data from the same samples run using the bead-based immunoassay at CDC, but comparisons will be limited by the lack of a reference standard. Finally, a reference standard would aid quality control and test development.

5. Recommendations

5.1 Existing and future data from these studies should be pooled and evaluated by modellers with expertise in trachoma, in order to extract as much information as possible and evaluate how to meaningfully relate indices based on nucleic acid amplification-based tests or antibodies to existing indicators. This work should include examination of quantitative antibody data in longitudinal studies. The robustness of any conclusions should be tested through the use of a number of different thresholds determined by different methods.

5.2 As soon as is practicable, appropriately de-identified data should be made available on collaborative data platforms, in order to encourage contributions from the widest possible scientific audience.

5.3 Efforts to collect primary data should continue. Such efforts should focus on the collection of longitudinal data through serial evaluation of the same evaluation units, and collection of data in countries that have already successfully undergone validation of elimination of trachoma as a public health problem, where well-documented serial estimates of active trachoma prevalence are available. Samples collected from individuals outside of the key indicator group are required to characterize the long-term serological and antibody patterns. WHO should play a role in encouraging national trachoma elimination programmes to participate in this work as implementation research, allied to the routine conduct of impact and surveillance surveys.

5.4 An international reference standard for serology is needed. A recombinant humanized antibody against Pgp3 should be commissioned by CDC.
References


### Annex 1. Meeting agenda

**Wednesday, 31 August 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:30</td>
<td>Welcome, Introductions, Purpose, outcome and outputs of meeting, Adoption of agenda, Administrative matters</td>
<td>Anthony Solomon, Patrick Lammie, Pamela Mbabazi, Patrick Lammie, Anthony Solomon</td>
</tr>
<tr>
<td>09:30–10:00</td>
<td>Background to the Trachoma Alternative Indicators Study</td>
<td>PJ Hooper</td>
</tr>
<tr>
<td>10:00–10:10</td>
<td>Systematic review of data on infection and active trachoma</td>
<td>Anthony Solomon</td>
</tr>
<tr>
<td>11:10–10:30</td>
<td>How much does it cost to train people to diagnose active trachoma?</td>
<td>Anthony Solomon</td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Testing for ocular <em>Chlamydia trachomatis</em> infection</td>
<td>Jeanne Moncada</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>PCR data from Uganda</td>
<td>Jeanne Moncada</td>
</tr>
<tr>
<td>12:00–14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00–14:30</td>
<td>PCR data from the Lao People’s Democratic Republic</td>
<td>Steph Migchelsen</td>
</tr>
<tr>
<td>14:30–15:00</td>
<td>PCR data from Malawi</td>
<td>Sarah Burr</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>PCR data from Ghana</td>
<td>Laura Senyonjo</td>
</tr>
<tr>
<td>16:00–16:30</td>
<td>PCR data from the United Republic of Tanzania and Nepal</td>
<td>Sheila West</td>
</tr>
<tr>
<td>16:30–17:00</td>
<td>Potential programmatic use of PCR for impact and surveillance surveys</td>
<td>All</td>
</tr>
</tbody>
</table>

**Thursday, 1 September 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:30</td>
<td>Principles of and tools for sero-surveillance in trachoma elimination</td>
<td>Diana Martin</td>
</tr>
<tr>
<td>09:30–10:00</td>
<td>How should we determine cut-offs?</td>
<td>Steph Migchelsen</td>
</tr>
<tr>
<td>10:00–10:30</td>
<td>Antibody data from the United Republic of Tanzania and Nepal</td>
<td>Sheila West</td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Antibody data from Ghana</td>
<td>Laura Senyonjo</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>Antibody data from Malawi</td>
<td>Sarah Burr</td>
</tr>
<tr>
<td>12:00–14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00–14:30</td>
<td>Antibody data from Uganda, the Lao People’s Democratic Republic and the Gambia</td>
<td>Steph Migchelsen</td>
</tr>
<tr>
<td>14:30–15:00</td>
<td>How should we put these data together to aid policy development?</td>
<td>Tom Lietman</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>15:30–17:00</td>
<td>Next steps, meeting feedback and close</td>
<td>All</td>
</tr>
</tbody>
</table>
Annex 2. List of participants

Robin Bailey  robin.bailey@lshtm.ac.uk
Sarah Burr  sarah.burr@lshtm.ac.uk
PJ Hooper  phooper@taskforce.org
Baforday Jatta  bjatta@hotmail.co.uk
Patrick Lammie  pjl1@cdc.gov
Tom Lietman  tom.lietman@ucsf.edu
David Mabey  david.mabey@lshtm.ac.uk
Diana Martin  hzx3@cdc.gov
Pamela Mbabazi  mbabazip@who.int
Stephanie Migchelsen  stephanie.migchelsen@lshtm.ac.uk
Jeanne Moncada  jeanne.moncada@ucsf.edu
Rosanna Peeling  rosanna.peeling@lshtm.ac.uk
Sophie Phelan  sophie.phelan@hotmail.com
Amy Pinsent  amy.pinsent@monash.edu
Laura Senyonjo  lsenyonjo@sightsavers.org
Anthony Solomon  solomona@who.int
Sheila West  shwest@jhmi.edu